RRC ID |
35682
|
Author |
Ishikawa R, Amano Y, Kawakami M, Sunohara M, Watanabe K, Kage H, Ohishi N, Yatomi Y, Nakajima J, Fukayama M, Nagase T, Takai D.
|
Title |
The chimeric transcript RUNX1-GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer.
|
Journal |
Jpn J Clin Oncol
|
Abstract |
Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimera was detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although there was no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1-GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.
|
Volume |
46(2)
|
Pages |
185-9
|
Published |
2016-2-1
|
DOI |
10.1093/jjco/hyv187
|
PII |
hyv187
|
PMID |
26685324
|
PMC |
PMC4731000
|
MeSH |
Aged
Biomarkers, Tumor / analysis*
Carcinoma, Non-Small-Cell Lung / chemistry*
Carcinoma, Non-Small-Cell Lung / pathology*
Chimera
Core Binding Factor Alpha 2 Subunit / analysis*
Female
Glutaredoxins / analysis*
Humans
Lung Neoplasms / chemistry*
Lung Neoplasms / pathology*
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Postoperative Period
Predictive Value of Tests
Prognosis
Survival Analysis
|
IF |
1.914
|
Times Cited |
0
|
WOS Category
|
ONCOLOGY
|
Resource |
DNA material |
CSII-CMV-MCS-IRES2-Bsd (RDB04385) |